Overall, the company from Vevey reported revenue of CHF 22.6 billion in the first three months of the new year, as announced ...

At the capital markets day at the end of March, Kühne + Nagel revised its strategy named «Roadmap 26.» Previously, the focus ...

The pharmaceutical and diagnostics company slightly exceeded expectations in the first quarter, driven by its pharmaceutical ...

Roche slightly surpassed revenue expectations in the first three months. The company reaffirms its full-year guidance.

Fears are growing in the EU that sanctions against Russia may expire in July. Options for frozen foreign exchange reserves ...

Following competitor Novartis, pharma giant Roche also announces massive investments in the United States. Swiss jobs and ...

After Accelleron, ABB is preparing its next billion dollar IPO. The new CEO is making his mark and delivers good results. Morten Wierod has taken little time to set a new course at ABB. In his ninth ...

Philip Morris shares have risen by more than 50% in the past twelve months – the transformation is going well. In an interview, European CEO Massimo Andolina explains why there is no longer a future ...

The US insurer Willis Towers Watson is an alternative to defensive US stocks from the food industry. The business is considered highly recession-resistant. Anyone investing in the highly nervous US ...

Following the recent near-financial crash, calls to exclude US government bonds from banks’ capital ratios are growing louder again. US government bonds are an extremely important tool for the ...

Six investment professionals tell our readers how to navigate in view of new US trade barriers. Today Philipp Lienhardt, Head of Equity Research at Julius Baer, reveals his tips. «Finanz und ...

The Fed’s interest rate pause, closed capital markets, the tariff storm, and mass layoffs at the U.S. FDA create a ...